Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 5 , Pages 575-596 , October 2009

The prolactinoma

  • Annamaria Colao, MD, PhD (Professor of Endocrinology)

      Affiliations

    • Corresponding Author InformationTel.: +39 81 7462132; Fax: +39 81 7463668.

References 

  1. Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocrine Reviews. 2006;27:485–534
  2. Schlechte JA. Clinical practice. Prolactinoma. The New England Journal of Medicine. 2003;349:2035–2041
  3. Colao A, Lombardi G. Growth hormone and prolactin excess. Lancet. 1998;352:1455–1461
  4. Cunnah D, Besser M. Management of prolactinomas. Clinical Endocrinology. 1991;34:231–235
  5. Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. The Journal of Clinical Endocrinology Metabolism. 2006;91:4769–4775
  6. Colao A, Sarno AD, Cappabianca P, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. European Journal of Endocrinology. 2003;148:325–331
  7. Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clinical Endocrinology. 1994;41:359–364
  8. Colao A. Pituitary tumors in childhood. In: New MI [ed] Endotext.org, 2004.
  9. Burgess JR, Shepard JJ, Parameswaran V, et al. Prolactinomas in a large kindred with multiple endocrine neoplasia type 1: clinical features and inheritance pattern. The Journal of Clinical Endocrinology Metabolism. 1996;81:1841–1845
  10. Vergès B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 [MEN1]: data from the France-Belgium MEN1 multicenter study. The Journal of Clinical Endocrinology Metabolism. 2002;87:457–465
  11. Burrow GN, Wortzman G, Rewcastle NB, et al. Microadenomas of the pituitary gland and abnormal sellar tomograms in an unselected autopsy series. The New England Journal of Medicine. 1980;304:156–158
  12. Delgrange E, Trouillas J, Maiter D, et al. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. The Journal of Clinical Endocrinology Metabolism. 1997;82:2102–2107
  13. Berezin M, Shimon I, Hadani M. Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma). Journal of Endocrinological Investigation. 1995;18:436–441
  14. Walsh JP, Pullan PT. Hyperprolactinaemia in males: a heterogeneous disorder. Australian and New Zealand Journal of Medicine. 1997;27:385–390
  15. Pinzone JJ, Katznelson L, Danila DC, et al. Primary medical therapy of micro- and macroprolactinomas in men. The Journal of Clinical Endocrinology Metabolism. 2000;85:3053–3057
  16. De Rosa M, Zarrilli S, Di Sarno A, et al. Hyperprolactinemia in men. Clinical and biochemical features and response to treatment. Endocrine. 2003;20(1–2):75–82
  17. Johri AM, Heaton JP, Morales A. Severe erectile dysfunction is a marker for hyperprolactinemia. International Journal of Impotence Research. 2001;13:176–182
  18. Rehman J, Christ G, Alyskewycz M, et al. Experimental hyperprolactinemia in a rat model: alteration in centrally mediated neuroerectile mechanism. International Journal of Impotence Research. 2000;12:23–32
  19. De Rosa M, Zarrilli S, Vitale G, et al. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. The Journal of Clinical Endocrinology Metabolism. 2004;89(2):621–625
  20. Naliato EC, Violante AH, Caldas D, et al. Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clinical Endocrinology. 2007;67:845–852
  21. Greenspan SL, Oppenheim DS, Klibanski A. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Annals of Internal Medicine. 1989;110:526–531
  22. Kayath MJ, Lengyel AM, Vieira JG. Prevalence and magnitude of osteopenia in patients with prolactinoma. Brazilian Journal of Medical and Biological Research. 1993;26:933–941
  23. Colao A, Di Somma C, Loche S, et al. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clinical Endocrinology. 2000;52:319–327
  24. Kars M, van der Klaauw AA, Onstein CS, et al. Quality of life is decreased in female patients treated for microprolactinoma. European Journal of Endocrinology. 2007;157:133–139
  25. Cesar de Oliveira Naliato E, Dutra Violante AH, Caldas D, et al. Quality of life in women with microprolactinoma treated with dopamine agonists. Pituitary. 2008;11:247–254
  26. Di Sarno A, Rota F, Auriemma R, et al. An evaluation of patients with hyperprolactinemia: have dynamic tests had their day?. Journal of Endocrinological Investigation. 2003;26(7 Suppl.):39–47
  27. Cavaco B, Leite V, Santos MA, et al. Some forms of big big prolactin behave as a complex of monomeric with an immunoglobulin G in patients with macroprolactinoma or prolactinomas. The Journal of Clinical Endocrinology Metabolism. 1995;80:3507–3512
  28. Hattori N, Ikekubo K, Ishihara T, et al. Effects of antiprolactin autoantibodies on serum prolactin measurements. European Journal of Endocrinology. 1994;130:434–437
  29. Petakov MS, Damjanovic' SS, Nikolic'-Durovic' MM, et al. Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. Journal of Endocrinological Investigation. 1998;21:184–188
  30. Biller BM. Diagnostic evaluation of hyperprolactinemia. The Journal of Reproductive Medicine. 1999;44(12 Suppl.):1095–1099
  31. Koppelman MC, Jaffe MJ, Rieth KG, et al. Hyperprolactinemia, amenorrhea, and galactorrhea. A retrospective assessment of twenty-five cases. Annals of Internal Medicine. 1984;100:115–121
  32. March CM, Kletzky OA, Davajan V, et al. Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. American Journal of Obstetrics and Gynecology. 1981;139:835–844
  33. Schlechte J, Dolan K, Sherman B, et al. The natural history of untreated hyperprolactinemia: a prospective analysis. The Journal of Clinical Endocrinology Metabolism. 1989;68:412–418
  34. Sisam DA, Sheehan JP, Sheeler LR. The natural history of untreated microprolactinomas. Fertility and Sterility. 1987;48:67–71
  35. Von Werder K, Eversmann T, Fahlbusch R, et al. Development of hyperprolactinemia in patients with adenomas with and without prior operative treatment. Excerpta Medica International Congress series. 1982;584:175–188
  36. Weiss MH, Teal J, Gott P, et al. Natural history of microprolactinomas: six-year follow-up. Neurosurgery. 1983;12:180–183
  37. Hofle G, Gasser R, Mohsenipour I, et al. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study. Experimental and Clinical Endocrinology & Diabetes. 1998;106:211–216
  38. Watt A, Pobereskin L, Vaidya B. Pituitary apoplexy within a macroprolactinoma. Nature Clinical Practice Endocrinology & Metabolism. 2008;4:635–641
  39. Jho HD. Endoscopic pituitary surgery. Pituitary. 1999;2:139–154
  40. Cappabianca P, Cavallo LM, de Divitiis E. Endoscopic endonasal transsphenoidal surgery. Neurosurgery. 2004;55:933–940discussion 940–1
  41. Cappabianca P, Cavallo LM, Colao A, et al. Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas. Journal of Neurosurgery. 2002;97:293–298
  42. Zada G, Kelly DF, Cohan P, et al. Endonasal transsphenoidal approach for pituitary adenomas and other sellar lesions: an assessment of efficacy, safety, and patient impressions. Journal of Neurosurgery. 2003;98:350–358
  43. Cho DY, Liau WR. Comparison of endonasal endoscopic surgery and sublabial microsurgery for prolactinomas. Surgical Neurology. 2002;58:371–375discussion 375–6
  44. Kawamata T, Iseki H, Ishizaki R, et al. Minimally invasive endoscope-assisted endonasal trans-sphenoidal microsurgery for pituitary tumors: experience with 215 cases comparing with sublabial trans-sphenoidal approach. Neurological Research. 2002;24:259–265
  45. Charpentier G, de Plunkett T, Jedynak P, et al. Surgical treatment of prolactinomas. Short- and long-term results, prognostic factors. Hormone Research. 1985;22:222–227
  46. Fahlbusch R, Buchfelder M. Present status of neurosurgery in the treatment of prolactinomas. Neurosurgical Review. 1985;8:195–205
  47. Landolt AM. Surgical treatment of pituitary prolactinomas: postoperative prolactin and fertility in seventy patients. Fertility and Sterility. 1981;35:620–625
  48. Rawe SE, Williamson HO, Levine JH, et al. Prolactinomas: surgical therapy, indications and results. Surgical Neurology. 1980;14:161–167
  49. Scanlon MF, Peters JR, Thomas JP, et al. Management of selected patients with hyperprolactinaemia by partial hypophysectomy. British Medical Journal (Clinical Research Ed). 1985;291:1547–1550
  50. Serri O, Rasio E, Beauregard H, et al. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. The New England Journal of Medicine. 1983;309:280–283
  51. Nicola GC, Tonnarelli GP, Griner A. One hundredand ten prolactin secreting adenomas: results of surgical treatment. In:  Faglia G,  Giovanelli M,  MacLeod RM editor. Pituitary microadenomas. New York: Academic Press; 1980;p. 483–486
  52. Faria MA, Tindall GT. Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas. Journal of Neurosurgery. 1982;56:33–43
  53. Randall RV, Laws ER, Abboud CF, et al. Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas. Results in 100 patients. Mayo Clinic Proceedings Mayo Clinic. 1983;58:108–121
  54. Hardy J. Transsphenoidal microsurgery of prolactinomas. In:  Black PM,  Zervas NT,  Ridgway EC editor. Secretory tumors of the pituitary gland. New York: Raven Press; 1984;p. 73–81
  55. Arafah BM, Brodkey JS, Pearson OH. Gradual recovery of lactotroph responsiveness to dynamic stimulation following surgical removal of prolactinomas: long-term follow-up studies. Metabolism. 1986;35:905–912
  56. Guidetti B, Fraioli B, Cantore GP. Results of surgical management of 319 pituitary adenomas. Acta Neurochirurgica. 1987;85:117–124
  57. Giovanelli M, Losa M, Mortini P, et al. Surgical results in microadenomas. Acta Neurochirurgica. 1996;65(Suppl.):11–12
  58. Tyrrell JB, Lamborn KR, Hannegan LT, et al. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery. 1999;44:254–261discussion 261–3
  59. Gokalp HZ, Deda H, Attar A, et al. The neurosurgical management of prolactinomas. Journal of Neurosurgical Sciences. 2000;44:128–132
  60. Amar AP, Couldwell WT, Chen JC, et al. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. Journal of Neurosurgery. 2002;97:307–314
  61. Mortini P, Losa M, Barzaghi R, et al. Results of transsphenoidal surgery in a large series of patients with pituitary adenoma. Neurosurgery. 2005;56:1222–1233discussion 1233
  62. Ciccarelli E, Ghigo E, Miola C, et al. Long-term follow-up of ‘cured’ prolactinoma patients after successful adenomectomy. Clinical Endocrinology. 1990;32:583–592
  63. Massoud F, Serri O, Hardy J, et al. Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up. Surgical Neurology. 1996;45:341–346
  64. Thomson JA, Gray CE, Teasdale GM. Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up. Neurosurgery. 2002;50:36–39discussion 39–40
  65. Pan L, Zhang N, Wang EM, et al. Gamma knife radiosurgery as a primary treatment for prolactinomas. Journal of Neurosurgery. 2000;93(Suppl. 3):10–13
  66. Landolt AM, Lomax N. Gamma knife radiosurgery for prolactinomas. Journal of Neurosurgery. 2000;93(Suppl. 3):14–18
  67. Rocher FP, Sentenac I, Berger C, et al. Stereotactic radiosurgery: the Lyon experience. Acta Neurochirurgica. 1995;63(Suppl.):109–114
  68. Leber KA, Bergloff J, Pendl G. Dose-response tolerance of the visual pathways and cranial nerves of the cavernous sinus to stereotactic radiosurgery. Journal of Neurosurgery. 1998;88:43–50
  69. Tishler RB, Loeffler JS, Lunsford LD, et al. Tolerance of cranial nerves of the cavernous sinus to radiosurgery. International Journal of Radiation Oncology, Biology, Physics. 1993;27:215–221
  70. Brada M, Ajithkumar TV, Minniti G. Radiosurgery for pituitary adenomas. Clinical Endocrinology. 2004;61:531–534
  71. Chen JC, Giannotta SL, Yu C, et al. Radiosurgical management of benign cavernous sinus tumors: dose profiles and acute complications. Neurosurgery. 2001;48:1022–1030discussion 1030–2
  72. Snyder PJ, Fowble BF, Schatz NJ, et al. Hypopituitarism following radiation therapy of pituitary adenomas. The American Journal of Medicine. 1986;81:457–462
  73. Littley MD, Shalet SM, Beardwell CG, et al. Hypopituitarism following external radiotherapy for pituitary tumours in adults. The Quarterly Journal of Medicine. 1989;70:145–160
  74. Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 2001;357:425–431
  75. Erfurth EM, Bulow B, Mikoczy Z, et al. Is there an increase in second brain tumours after surgery and irradiation for a pituitary tumour?. Clinical Endocrinology. 2001;55:613–616
  76. Minniti G, Traish D, Ashley S, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. The Journal of Clinical Endocrinology Metabolism. 2005;90:800–804
  77. Hoybye C, Grenback E, Rahn T, et al. Adrenocorticotropic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery. Neurosurgery. 2001;49:284–291discussion 291–2
  78. Witt TC. Stereotactic radiosurgery for pituitary tumors. Neurosurg Focus. 2003;14:e10
  79. Sheehan JP, Niranjan A, Sheehan JM, et al. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. Journal of Neurosurgery. 2005;102:678–691
  80. Colao A, Annunziato L, Lombardi G. Treatment of prolactinomas. Annals of Internal Medicine. 1998;30:452–459
  81. Colao A, Di Sarno A, Pivonello R, et al. Dopamine receptor agonists for treating prolactinomas. Expert Opinion on Investigational Drugs. 2002;11:787–800
  82. Klibanski A, Greenspan SL. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. The New England Journal of Medicine. 1986;315:542–546
  83. Di Somma C, Colao A, Di Sarno A, et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. The Journal of Clinical Endocrinology Metabolism. 1998;83:807–813
  84. De Rosa M, Colao A, Di Sarno A, et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. European Journal of Endocrinology. 1998;138:286–293
  85. Di Sarno A, Landi ML, Cappabianca P, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. The Journal of Clinical Endocrinology Metabolism. 2001;86:5256–5261
  86. Colao A, Pivonello R, Di Somma C, et al. Medical therapy of pituitary adenomas: effects on tumor shrinkage. Reviews in Endocrine & Metabolic Disorders. 2008 Sep 13;[Epub ahead of print]
  87. Colao A, Di Sarno A, Landi ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. The Journal of Clinical Endocrinology Metabolism. 2000;85:2247–2252
  88. Lamberts SW, Quik RF. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. The Journal of Clinical Endocrinology Metabolism. 1991;72:635–641
  89. Colao A, De Rosa M, Sarnacchiaro F, et al. Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. European Journal of Endocrinology. 1996;135:548–552
  90. Liuzzi A, Dallabonzana D, Oppizzi G, et al. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. The New England Journal of Medicine. 1985;313:656–659
  91. Dallabonzana D, Liuzzi A, Oppizzi G, et al. Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride. The Journal of Clinical Endocrinology Metabolism. 1986;63:1002–1007
  92. Turner TH, Cookson JC, Wass JA, et al. Psychotic reactions during treatment of pituitary tumours with dopamine agonists. British Medical Journal (Clinical Research Ed). 1984;289:1101–1103
  93. Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. The New England Journal of Medicine. 2007;356:39–46
  94. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. The New England Journal of Medicine. 2007;356:29–38
  95. Lancellotti P, Livadariu E, Markov M, et al. Cabergoline and the risk of valvular lesions in endocrine disease. European Journal of Endocrinology. 2008;159:1–5
  96. Vallette S, Serri K, Rivera J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary. 2008 Jul 2;[Epub ahead of print]
  97. Kars M, Delgado V, Holman ER, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. The Journal of Clinical Endocrinology Metabolism. 2008;93:3348–3356
  98. Devin JK, Lakhani VT, Byrd BF, et al. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocrine Practice. 2008;14:672–677
  99. Colao A, Galderisi M, Di Sarno A, et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. The Journal of Clinical Endocrinology Metabolism. 2008;93:3777–3784
  100. Wakil A, Rigby AS, Clark AL, et al. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. European Journal of Endocrinology. 2008;159:R11–R14
  101. Bogazzi F, Buralli S, Manetti L, et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. International Journal of Clinical Practice. 2008;62:1864–1869
  102. Herring N, Szmigielski C, Becher H, et al. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clinical Endocrinology. 2009;70:104–108
  103. Ono M, Miki N, Kawamata T, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. The Journal of Clinical Endocrinology Metabolism. 2008;93:4721–4727
  104. Nachtigall LB, Valassi E, McCaty D, et al. Cardiac valvular function in hyperprolactinemic patients receiving cabergoline. Program of the 90th Annual Meeting of The Endocrine Society, San Francisco, CA, 2008, p 124 [Abstract OR27-2].
  105. Kars M, Pereira AM, Bax JJ, et al. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. European Journal of Endocrinology. 2008;159:363–367
  106. Johnston DG, Prescott RW, Kendall-Taylor P, et al. Hyperprolactinemia. Long-term effects of bromocriptine. Annals of Internal Medicine. 1983;75:868–874
  107. Colao A, Di Sarno A, Cappabianca P, et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. The New England Journal of Medicine. 2003;349:2023–2033
  108. Zarate A, Canales ES, Cano C, et al. Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinologica. 1983;104:139–142
  109. Johnston DG, Hall K, Kendall-Taylor P, et al. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography. Lancet. 1984;2:187–192
  110. Maxson WS, Dudzinski M, Handwerger SH, et al. Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors. Fertility and Sterility. 1984;41:218–223
  111. Moriondo P, Travaglini P, Nissim M, et al. Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. The Journal of Clinical Endocrinology Metabolism. 1985;60:764–772
  112. Winkelmann W, Allolio B, Deuss U, et al. Persisting normoprolactinemia after withdrawal of bromocriptine long-term therapy in patients with prolactinomas. In:  MacLeod RM,  Thorner MO,  Scapagnini U editor. Basic and clinical correlates. Padova: Liviana Press; 1985;p. 817–822
  113. Wang C, Lam KS, Ma JT, et al. Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal. Clinical Endocrinology. 1987;27:363–371
  114. Rasmussen C, Brownell J, Bergh T. Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502. Acta Endocrinologica. 1991;125:170–176
  115. van't Verlaat JW, Croughs RJ. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clinical Endocrinology. 1991;34:175–178
  116. Passos VQ, Souza JJ, Musolino NR, et al. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. The Journal of Clinical Endocrinology Metabolism. 2002;87:3578–3582
  117. Biswas M, Smith J, Jadon D, et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clinical Endocrinology. 2005;63:26–31
  118. Di Sarno A, Landi ML, Marzullo P, et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clinical Endocrinology. 2000;53:53–60
  119. Ferrari C, Paracchi A, Mattei AM, et al. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinologica. 1992;126:489–494
  120. Muratori M, Arosio M, Gambino G, et al. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. Journal of Endocrinological Investigation. 1997;20:537–546
  121. Cannavò S, Curto L, Squadrito S, et al. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. Journal of Endocrinological Investigation. 1999;22:354–359
  122. Colao A, Di Sarno A, Guerra E, et al. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clinical Endocrinology. 2007;67:426–433
  123. Crosignani PG, Mattei AM, Severini V, et al. Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 1992;44:175–180
  124. Jeffcoate WJ, Pound N, Sturrock ND, et al. Long-term follow-up of patients with hyperprolactinaemia. Clinical Endocrinology. 1996;45:299–303
  125. Karunakaran S, Page RC, Wass JA. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clinical Endocrinology. 2001;54:295–300
  126. Molitch ME. The cabergoline-resistant prolactinoma patient: new challenges. The Journal of Clinical Endocrinology Metabolism. 2008;93:4643–4645
  127. Bression D, Brandi AM, Martres MP, et al. Dopaminergic receptors in human prolactin-secreting adenomas: a quantitative study. The Journal of Clinical Endocrinology Metabolism. 1980;51:1037–1044
  128. Pellegrini I, Rasolonjanahary R, Gunz , et al. Resistance to bromocriptine in prolactinomas. The Journal of Clinical Endocrinology Metabolism. 1989;69:500–509
  129. Caccavelli L, Feron F, Morange I, et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology. 1994;60:314–322
  130. Friedman E, Adams EF, Hoog A, et al. Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors. The Journal of Clinical Endocrinology Metabolism. 1994;78:568–574
  131. Filopanti M, Barbieri AM, Angioni AR, et al. Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. The Pharmacogenomics Journal. 2008;8:357–363
  132. Dallabonzana D, Spelta B, Oppizzi G, et al. Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases. Journal of Endocrinological Investigation. 1983;6:47–50
  133. Breidahl HD, Topliss DJ, Pike JW. Failure of bromocriptine to maintain reduction in size of a macroprolactinoma. British Medical Journal (Clinical Research Ed). 1983;287:451–452
  134. Winkelmann J, Pagotto U, Theodoropoulou M, et al. Retention of dopamine 2 receptor mRNA and absence of the protein in craniospinal and extracranial metastasis of a malignant prolactinoma: a case report. European Journal of Endocrinology. 2002;146:81–88
  135. Delgrange E, Crabbe J, Donckier J. Late development of resistance to bromocriptine in a patient with macroprolactinoma. Hormone Research. 1998;49:250–253
  136. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. The Journal of Clinical Endocrinology Metabolism. 1999;84:2518–2522
  137. Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. The Journal of Clinical Endocrinology Metabolism. 1997;82:876–883
  138. Brue T, Pellegrini I, Gunz G, et al. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. The Journal of Clinical Endocrinology Metabolism. 1992;74:577–584
  139. Glaser B, Nesher Y, Barziliai S. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502. The Journal of Reproductive Medicine. 1994;39:449–454
  140. Morange I, Barlier A, Pellegrini I, et al. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. European Journal of Endocrinology. 1996;135:413–420
  141. De Luis DA, Becerra A, Lahera M, et al. A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients. Journal of Endocrinological Investigation. 2000;23:428–434
  142. Webster J. Cabergoline and quinagolide therapy for prolactinomas. Clinical Endocrinology. 2000;53:549–550
  143. Ahmed SR, Shalet SM. Discordant responses of prolactinoma to two different dopamine agonists. Clinical Endocrinology. 1986;24:421–426
  144. Berezin M, Avidan D, Baron E. Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs. Israel Journal of Medical Sciences. 1991;27:375–379
  145. Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. The Journal of Clinical Endocrinology Metabolism. 1985;60:698–705
  146. Freda PU, Andreadis CI, Khandji AG, et al. Long-term treatment of prolactin-secreting macroadenomas with pergolide. The Journal of Clinical Endocrinology Metabolism. 2000;85:8–13
  147. Colao A, Ochoa AS, Auriemma RS, et al. Pituitary carcinomas. Frontiers of Hormone Research, in press.
  148. Radwanska E, McGarrigle HH, Little V, et al. Induction of ovulation in women with hyperprolactinemic amenorrhea using clomiphene and human chorionic gonadotropin of bromocriptine. Fertility and Sterility. 1979;32:187–192
  149. Bergh T, Skarin G, Nillius SJ, et al. Pulsatile GnRH therapy–an alternative successful therapy for induction of ovulation in infertile normo- and hyperprolactinaemic amenorrhoeic women with pituitary tumours. Acta Endocrinologica. 1985;110:440–444
  150. Gindoff PR, Loucopoulos A, Jewelewicz R. Treatment of hyperprolactinemic amenorrhea with pulsatile gonadotropin-releasing hormone therapy. Fertility and Sterility. 1986;46:1156–1158
  151. McGarrigle HH, Sarris S, Little V, et al. Induction of ovulation with clomiphene and human chorionic gonadotrophin in women with hyperprolactinaemic amenorrhoea. British Journal of Obstetrics and Gynaecology. 1978;85:692–697
  152. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. The European Recombinant Human LH Study Group. The Journal of Clinical Endocrinology Metabolism. 1998;83:1507–1514
  153. Divers WA, Yen SS. Prolactin-producing microadenomas in pregnancy. Obstetrics and Gynecology. 1983;62:425–429
  154. Colao A, Abs R, Bárcena DG, et al. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clinical Endocrinology. 2008;8(1):66–71
  155. Belchetz PE, Carty A, Clearkin LG, et al. Failure of prophylactic surgery to avert massive pituitary expansion in pregnancy. Clinical Endocrinology. 1986;25:325–330
  156. Ruiz-Velasco V, Tolis G. Pregnancy in hyperprolactinemic women. Fertility and Sterility. 1984;41:793–805
  157. Molitch ME. Pituitary disorders during pregnancy. Endocrinology and Metabolism Clinics of North America. 2006;35(1):99–116

PII: S1521-690X(09)00047-5

doi: 10.1016/j.beem.2009.05.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 5 , Pages 575-596 , October 2009

Article Tools

* Image Usage & Resolution